Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
The associate professor of medicine at University of Colorado discussed updated follow-up data from the phase 3 TRANSFORM trial presented at the 2024 ASCO meeting.
“The FDA approved liso-cel as a second line option for patients with primary refractory and early relapsed large B cell lymphoma if they're transplant eligible based on the TRANSFORM study. So, I think this 3-year update is important to figure out if all of these analyses hold true. The short answer is yes, they do”
Lisocabtagene maraleucel (liso-cel) has continued to demonstrate superiority over standard of care in patients with primary refractory/relapsed (r/r) large B-cell lymphoma (LBCL) with deep responses.1 The therapy was approved under the name Breyanzi for patients with LBCL whose disease was r/r to first-line treatment within 12 months and patients with LBCL whose disease was r/r to first-line treatment who are not eligible for hematopoietic stem cell transplant based off of the primary analysis of the phase 3 TRANSFORM trial (NCT03575351) in 2022.
Updated, 3-year data from TRANSFORM were presented at the
REFERENCES
1. Kamdar MK, Solomon SR, Arnason J, et al. Lisocabtagenemaraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7013
2. US FDA approves Bristol Myers Squibb’s CAR T Cell therapy Breyanzi® for relapsed or refractory large B-cell lymphoma after one prior therapy. News release. Bristol Myers Squibb. June 24, 2022. Accessed June 3, 2024. https://news.bms.com/news/details/2022/US-FDA-Approves-Bristol-Myers-Squibbs-CAR-T-Cell-Therapy-Breyanzifor-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-One-Prior-Therapy/default.aspx
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025